SEPTRA DS Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Septra Ds, and when can generic versions of Septra Ds launch?

Septra Ds is a drug marketed by Monarch Pharms and is included in one NDA.

The generic ingredient in SEPTRA DS is sulfamethoxazole; trimethoprim. There are twenty-seven drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the sulfamethoxazole; trimethoprim profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Septra Ds

A generic version of SEPTRA DS was approved as sulfamethoxazole; trimethoprim by SUN PHARM INDUSTRIES on August 25^th, 1986.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for SEPTRA DS?
What are the global sales for SEPTRA DS?
What is Average Wholesale Price for SEPTRA DS?

Summary for SEPTRA DS

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	23
DailyMed Link:	SEPTRA DS at DailyMed

Drug patent expirations by year for SEPTRA DS

Recent Clinical Trials for SEPTRA DS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Roswell Park Cancer Institute	Phase 4
National Cancer Institute (NCI)	Phase 4
Cidara Therapeutics Inc.	Phase 3

See all SEPTRA DS clinical trials

US Patents and Regulatory Information for SEPTRA DS

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Monarch Pharms	SEPTRA DS	sulfamethoxazole; trimethoprim	TABLET;ORAL	017376-002	Approved Prior to Jan 1, 1982	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SEPTRA DS

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Monarch Pharms	SEPTRA DS	sulfamethoxazole; trimethoprim	TABLET;ORAL	017376-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for SEPTRA DS

See the table below for patents covering SEPTRA DS around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
German Democratic Republic	118228		⤷ Sign Up
Philippines	14575	AN IMPROVED TABLET FORMULATION	⤷ Sign Up
Norway	750467		⤷ Sign Up
Cyprus	1052	TABLET FORMULATION	⤷ Sign Up
Zambia	2976	TABLET FORMULATION	⤷ Sign Up
Sweden	427898	SETT ATT FRAMSTELLA TABLETTER MED KORT SONDERDELNINGSTID INNEHALLANDE 2,4-DIAMINO-5-(3,4,5-TRIMETOXIBENSYL)PYRIMIDIN OCH 3-(4-AMINOBENSENSULFONAMIDO)-5-METYLISOXAZOL	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for SEPTRA DS

Recent Clinical Trials for SEPTRA DS

Make Better Decisions: Try a trial or see plans & pricing